Bronchoscopic multimodality lung tumor treatment

Information

  • Patent Grant
  • 11350988
  • Patent Number
    11,350,988
  • Date Filed
    Wednesday, August 22, 2018
    5 years ago
  • Date Issued
    Tuesday, June 7, 2022
    a year ago
Abstract
A minimally invasive medical technique for treating lung tumors includes use of multiple ablation modalities in a single procedure. Condensable vapor ablation and electrosurgical ablation are applied to treat the surface of the tumor and to debulk inner regions of the tumor, respectively.
Description
BACKGROUND OF THE INVENTION

The present invention relates to medical methods for treating lung tumors, and more specifically to minimally invasive medical methods for ablating lung tumors.


Bronchoscopic radio frequency ablation and bronchoscopic thermal vapor ablation are examples of minimally invasive techniques to treat lung tumors in a patient.


Bronchoscopic radio frequency ablation involves navigating an ablation catheter through the airways of the patient and to the lung tumor. The ablation catheter is activated, delivering radio frequency energy to the tumor. The physician targets or focuses the energy towards the center of the tumor to minimize damage to healthy tissue adjacent the tumor.


A drawback of radio frequency ablation is that targeting the center of the lung tumor risks allowing the margin of the tumor to remain untreated. This is undesirable.


Increasing the energy delivered to the tumor, however, is also undesirable due to the likelihood of overheating the healthy tissue adjacent the tumor.


Another drawback of bronchoscopic radio frequency ablation arises from the structural limitations of the ablation electrodes and the available spacing to maneuver the electrodes. To compensate, the physician may elect to increase the energy delivered to the target. Increasing the energy delivered to the target tissue, however, risks causing collateral damage to healthy adjacent tissue.


Bronchoscopic thermal vapor ablation is another technique to treat lung tumors. Bronchoscopic thermal ablation sends a condensable vapor across the lung tumor. The vapor, upon contact with tissue, changes phase from gas to liquid, heating the outside of the lung tumor and ultimately serving to ablate the tumor. Bronchoscopic thermal vapor ablation heats the tumor from the outside to the inside. A challenge with bronchoscopic thermal vapor ablation is to quickly reach the center or inside of the lung tumor. Increasing the thermal energy delivered via the vapor is undesirable for risking collateral damage to healthy adjacent tissue.


Notwithstanding the above, minimally invasive methods and systems are still desired that effectively ablate lung tumors in a patient, and to do so without damaging the healthy adjacent tissue and without putting the patient at any further risk of infection. Accordingly, a method that overcomes the above mentioned challenges is desirable.


SUMMARY OF THE INVENTION

The present invention is a method for treating a suspect tissue mass such as, for example, a lung tumor or metastasis.


A minimally invasive medical technique for treating lung tumors includes use of multiple ablation modalities in a single procedure. Condensable vapor ablation and electrosurgical ablation are applied to treat the surface of the tumor and to debulk inner regions of the tumor, respectively.


In embodiments, a method of treating a suspect tissue mass in a lung comprises uniformly applying heat to the margin or exterior of the suspect tissue mass and discretely applying heat to interior portions of the suspect tissue mass.


In embodiments, the step of uniformly applying heat to the margin of the suspect tissue mass comprises delivering a condensable vapor around the suspect tissue mass.


In embodiments, the step of discretely applying heat to the interior of the suspect tissue mass comprises advancing an electrosurgical instrument into direct contact with the suspect tissue mass, and activating the instrument.


In embodiments, the step of discretely applying heat to the interior of the suspect tissue mass comprises placing a heat source at a discrete internal location (e.g., the center of the suspect tissue mass), and radiating heat from the heat source towards the exterior of the mass.


In embodiments, the electrosurgical instrument is an RF energy catheter.


In embodiments, the method further comprises assessing an exterior of the suspect tissue mass for uniformity prior to the step of heating by the first modality, and assessing an interior of the suspect tissue mass for density prior to the step of heating by the second modality. The steps of assessing may be performed preoperatively using CT or other imaging data, and analysis. Additionally, the step of assessing may be performed using ultrasound, bronchoscope or other diagnostic and imaging techniques. Should the suspect tissue mass be non-uniform or lack symmetry, heating is performed by delivering condensable vapor. The second modality is then carried out to heat from the inside out. In embodiments, the method further comprises monitoring a first ablation region growing inward and a second ablation region growing outward arising from the first modality and second modality of heating, respectively, and confirming an overlap zone between the first ablation region and second ablation region.


Still other descriptions, objects and advantages of the present invention will become apparent from the detailed description to follow, together with the accompanying drawings.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 a flow chart illustrating a method in accordance with one embodiment of the present invention.



FIGS. 2 and 3 are illustrations of a method for delivering a condensable vapor to ablate a lung tumor in accordance with one embodiment of the invention.



FIG. 4 is an illustration of a method for ablating a lung tumor by applying radio frequency energy in accordance with one embodiment of the invention.



FIG. 5 is a flow chart illustrating another method to treat a lung tumor outside of an airway in the lung of a patient.



FIG. 6 is an illustration of a method for treating a lung tumor via a plurality of implants in accordance with one embodiment of the invention.





DETAILED DESCRIPTION OF THE INVENTION

Before the present invention is described in detail, it is to be understood that this invention is not limited to particular variations set forth herein as various changes or modifications may be made to the invention described and equivalents may be substituted without departing from the spirit and scope of the invention. As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present invention. In addition, many modifications may be made to adapt a particular situation, material, composition of matter, process, process act(s) or step(s) to the objective(s), spirit or scope of the present invention. All such modifications are intended to be within the scope of the claims made herein.


Methods recited herein may be carried out in any order of the recited events which is logically possible, as well as the recited order of events. Furthermore, where a range of values is provided, it is understood that every intervening value, between the upper and lower limit of that range and any other stated or intervening value in that stated range is encompassed within the invention. Also, it is contemplated that any optional feature of the inventive variations described may be set forth and claimed independently, or in combination with any one or more of the features described herein.


All existing subject matter mentioned herein (e.g., publications, patents, patent applications and hardware) is incorporated by reference herein in its entirety except insofar as the subject matter may conflict with that of the present invention (in which case what is present herein shall prevail).


Reference to a singular item, includes the possibility that there are plural of the same items present. More specifically, as used herein and in the appended claims, the singular forms “a,” “an,” “said” and “the” include plural referents unless the context clearly dictates otherwise. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as “solely,” “only” and the like in connection with the recitation of claim elements, or use of a “negative” limitation.


Method Overview


An overview of a lung tumor treatment method 10 in accordance with embodiments of the present invention is illustrated in FIG. 1.


Step 12 states to identify a lung tumor or suspect tissue mass in the lung of the patient. By “suspect tissue mass”, it is meant a tissue mass whether diseased or otherwise a candidate for diagnosis, treatment or removal. Examples of a suspect tissue mass include, without limitation, a tumor, metastasis, growth, lymph node, tissue nodule, or other diseased tissue causing obstructions in the lung. Also, by “diseased lung tissue” it is meant a disorder or function in the lung tissue including, without limitation, emphysema, lung cancer or metastasis, TB, aspergillus, and pneumonia.


Physicians may identify the suspect tissue mass using imaging technology including, for example, CT scans, fluoroscopy, X-rays, and bronchoscopy.


Step 14 states to plan a route to the target tissue, e.g., the lung tumor. Though a physician may plan a route to the tumor by eye using the X-ray or video images of the lung and tumor, more sophisticated techniques automatically compute an optimal route to the target through the airways. Examples of airways include the trachea, bronchi, bronchial branches including, without limitation, the bronchioles and terminal bronchioles. Examples of route planning techniques are described in U.S. Pat. No. 9,037,215.


The next step shown in FIG. 1 is the first treatment procedure 15. By “first treatment procedure”, it is meant a single continuous medical operation or intervention without interruption (such as by patient discharge from the OR, hospital, or surgery center) and regardless of how many individual treatment modalities, described below, are performed on the patient during her first treatment procedure.


Step 16 states to apply a first treatment modality to ablate the tissue margin. The first treatment modality serves to ablate across the exterior surface of the lung tumor. As will be described further herein, an exemplary first modality treatment for ablating the tumor margin includes, without limitation, condensable vapor ablation. By “margin of the tumor” it is meant the outer region or boundary of the tumor. Examples of the margin of the tumor include the outer limits, boundary, outside, and periphery of the tumor.


Step 18 states to apply a second treatment modality to debulk target tissue. As will described further herein, an instrument is advanced along the route to the target tissue. Once the position of the working tip is confirmed, energy is applied to debulk the lung tumor. Exemplary techniques to debulk the lung tumor include, without limitation, electro-surgery, microwave ablation, and cryosurgery.


With reference to FIGS. 2 and 3 aspects of the invention are described in further detail. Particularly, FIG. 2 shows the respiratory system including the trachea 36, left lung lobe 32 and right lung lobe 34, left bronchi 24 and right bronchi 22 and lobar bronchial branches. The lobar bronchial branches further break off into segmental and sub-segmental branches. A lung tumor 400 is shown in the left lobe 32 in the vicinity of the left secondary bronchi 42 or segmental bronchi.


Bronchoscopic Condensable Vapor Ablation



FIG. 2 also illustrates a bronchoscope 100 having a working channel extending through the trachea 36 and into the left bronchi 24. Guidance of the bronchoscope to the target area in the lung may be performed by eye using the video monitor (not shown), under fluoroscopy, or using navigation or guidance systems. Examples of guidance and navigation systems are described in the U.S. Pat. Nos. 7,889,905 and 7,756,563.


Vapor ablation catheter 200 is shown advanced through the bronchoscope 100 and into the bronchi branch upstream or proximal to the lung tumor 400. Balloon 202 is inflated to isolate the target airways and tumor.


With reference to FIG. 3, a condensable vapor 210 is delivered from the end of the catheter 200 into the airways and tumor 400. The vapor surrounds or engulfs the tumor, quickly heating the tumor as the vapor changes to liquid phase. The margin of the tumor is initially heated by thermal convection, and then heat thermally conducts towards the center of the tumor until the tumor is ablated. In a sense, the tumor 400 is heated from the outside to the inside (namely, “outside in”).


An advantage of vapor ablation is that a wide range of tissue geometries may be treated because of the gaseous nature of the vapor. The catheter is not required to contact the target tissue. The vapor crosses any gaps present in the tissue until the tumor is completely engulfed or encapsulated by the vapor. Additionally, porous tissues near the tumor margin can be permeated by the vapor, and ablated.


The energy delivery or vapor ablation catheter 200 may have various configurations. Examples of vapor ablation catheters, energy generators and controllers are described in U.S. Pat. Nos. 7,913,698; 8,585,645, and US Patent Publication No. 2016/0151103. In some embodiments, the catheter is adapted to detachably couple to an energy generator (not shown).


Electrosurgical Ablation


As stated above, embodiments of the invention include treatment of a lung tumor with a second treatment modality such as, for example, radio frequency ablation. With reference to FIG. 4, a radio frequency probe 300 is shown advanced beyond the end of a sheath 302, and into the lung tumor 400. Although the distal tip of the electrosurgical instrument 300 is shown penetrating the tumor 400, the invention is not so limited. Embodiments of the invention include, without limitation, making mere contact with the tumor, or partially inserting the tip, or contacting a pole or edge of the tumor.


Once the physician confirms the catheter tip 300 or RF electrode is properly positioned, the radio frequency catheter is activated. Position confirmation or tracking of the catheters can be performed by a wide range of guidance and location techniques including, without limitation, fluoroscopy or use of electromagnetic sensors. Examples of tracking and guidance techniques are described in U.S. Pat. Nos. 6,380,732 and 9,265,468 and US Patent Publication no. 2016/0180529.


In embodiments, and with reference to FIG. 4, the tip 300 is a sharp needle pair and penetrates the lung tumor 400. The electrodes act as a heat source and initially heat the tissue where the electrodes make contact. The heat thermally conducts through the tumor from the heat source. When the tip is positioned within the tumor, the tumor is ablated from the heat source (or point) to the exterior (namely, “inside out”).


An advantage of RF ablation is that the central denser portion of the tumor can be efficiently ablated. This is particularly useful for larger tumors where the heat from the vapor ablation, described above, may take longer to reach the dense central portions of the tumor. RF ablation is effective to ablate dense tissues and to debulk large volumes of tissue compared to other modalities. In contrast, condensable vapor ablation is effective to ablate across an entire surface where the geometry of the surface may be non-uniform and less dense than the central portions of the tumor.


The radio frequency energy delivery catheter may take a wide range of configurations and the electrode shape itself may also vary widely. Examples of electrode shapes include, without limitation, needle, hook, basket, loop, helix, coil, forceps or clamp, tubular, and snare or lasso. The electrode distal section may also be configured to flex, turn, and steer using mechanical or thermal action. Examples of RF ablation catheters, energy generators, and controllers are described in U.S. Pat. Nos. 6,692,494; 7,022,088 and US Patent Publication No. 2013/0046296.


Additional modalities to abate the tumor may include catheters and probes configured to deliver microwave energy, cryo-energy, or other types of energy suited to ablate lung tumors.



FIG. 5 is a flow chart of another method 500 for treating tumors in accordance with embodiments of the present invention.


Similar to the method described above, step 510 states to identify the tumor in the lung of a patient. Step 510 may be performed as described above.


Step 520 queries whether the target is within an airway. If yes, the procedure may proceed substantially as outlined above in connection with the methods described above.


Particularly, step 530 states to plan the bronchoscopic route to the target tissue.


Step 540 states to advance the bronchoscope to a position along the airway in the vicinity of the target tissue, preferably with a clear view of the target to be ablated.


Step 550 states to advance the vapor ablation catheter through the bronchoscope and into position at the target tissue. The position of the catheter may be confirmed as described above.


Step 560 states to deliver condensable vapor to the exterior of the target tissue to ablate the target tissue. After treatment with the vapor, the vapor catheter is withdrawn from the patient.


Step 570 states to advance the electrosurgical ablation catheter through the bronchoscope and into contact with the target tissue. Position of the catheter may be confirmed as described above.


Step 580 states to activate the electrosurgical ablation catheter to ablate the target tissue. After ablation, the catheter is retracted from the patient.


Step 590 states to confirm target tissue ablation. The physician may monitor and confirm ablation of the tumor in real time using the bronchoscope, sensors including electrodes and thermocouples, or other imaging techniques. Ablation duration, tissue temperature, energy delivered, may also be monitored and the procedure may be terminated when a threshold level is attained.


Tumor Outside the Airway—Create Access Channel


With reference again to step 520, in the event the target is determined to be outside of the airway (e.g., in the parenchymal lung tissue), method 500 proceeds to step 522.


Step 522 states to plan the bronchoscopic route to an exit or egress opening along the airway and in the vicinity of the target tissue, and to plan a route extension from the egress opening to the target tissue.


In embodiments, planning an exit or egress opening from the airway and to the target tissue outside of the airway is performed based on a number of constraints. Examples of constraints include, without limitation, proximity to the target tissue, avoiding obstacles such as blood vessels, and physical limitations of the instruments to be used during the procedure such as size, flexibility, and bend constraints. Exemplary techniques to plan the route are descried in U.S. Pat. Nos. 8,709,034 and 9,037,215.


Step 524 states to advance the bronchoscope to a position along the airway in the vicinity of the candidate exit opening.


Step 526 states to create an access pathway to the target tissue. Particularly, step 526 states to create the opening through the airway wall, and tunnel to the tumor to create an access passage along the pre-planned route extension.


In an embodiment, the egress hole is created with a catheter fed through the bronchoscope having a sharp tip. An example of a needle catheter suitable to create the hole is described in U.S. Pat. No. 8,517,955.


In an embodiment, the hole is dilated. Openings may be enlarged using, for example, enlargeable members (e.g., balloon) or fixed tapered dilators.


An elongate tube is advanced through the hole and to the tumor. The tube may be advanced over a wire or needle, or the tube may be navigated to the tumor. In embodiments, the tube includes a removable obturator to prohibit the tube from becoming filled with tissue as the tube is advanced through the tissue.


Once the tube is in position, and the position is confirmed, the intermediate instruments such as an obturator, dilator, guidewire, or needles are retracted leaving an open channel through the tube. Position confirmation, or tracking, of the instruments for accessing the tumor can be performed by a wide range of guidance and location techniques including, without limitation, fluoroscopy or use of electromagnetic sensors. Examples of tracking and guidance techniques are described in U.S. Pat. Nos. 6,380,732 and 9,265,468 and US Patent Publication no. 2016/0180529.


Although a route extension has been described above, various techniques to create and install an access passageway to the tumor are described in the following patent publications including, without limitation, U.S. Pat. Nos. 8,784,400 and 8,709,034. See also, Anciano et al., Going Off Road The First Case Reports of the Use of the Transbronchial Access Tool With Electromagnetic Navigational Bronchoscopy, J Bronchol Intervent Pulmonol, Vol. 24, No. 3, July 2017.


Once the access passageway is installed (such as, e.g., the sheath 302 shown in FIG. 4), the procedure to treat the tumor may be performed as described herein with reference to steps 550-590, except the ablation instruments are advanced to the tumor through the access passageway instead of solely along the airway.


Therapeutic Agent Delivery Via Microspheres



FIG. 6 illustrates ablation of a lung tumor 620 by implanting a plurality of therapeutic agent delivery vehicles 612 in accordance with another embodiment of the invention.


Particularly, a number of particles or microspheres 612 are shown implanted in the vicinity of the tumor 620 and a condensable vapor 600 is delivered from the end of the catheter 610 into the target region.


The microspheres are adapted to temporarily hold and deliver a therapeutic agent to the tumor. The microspheres may be preloaded with the agent, and then implanted in the lung. The position of the microspheres may be detected under imaging such as, for example, radiography or MRI.


The size of the microspheres may vary. In embodiments, the microspheres range from between 0.1 and 1000 μm.


The material of the microspheres may also vary. Exemplary materials of the microspheres include, without limitation, polymer, glass, ceramic. Examples of microspheres are FluoSpheres (manufactured by Thermo Fisher, Eugene, Oreg.).


Examples of therapeutic agents to be delivered by the microspheres include, without limitation, chemotherapy drugs, checkpoint inhibitor, immunotherapy agents, antibiotics or antiseptic agents.


In embodiments, the microspheres release the therapeutic agent over time. In embodiments, the therapeutic agent is heat activated, and treats the tumor.


Optionally, additional energy (e.g., RF ablation) or other treatment and ablation modalities may be applied to the tumor. Preferably, multiple modalities are applied in only one first treatment procedure.


Alternative Embodiments

A wide range of energy modalities may be employed in accordance with the present invention. Examples of suitable energy modalities include RF, laser, microwave, cryogenic fluid, resistive heating, ultrasound and other energy delivery mechanisms for heating a target lung volume.


In another embodiment, a method of treating a suspect tissue mass comprises: delivering a heat activated therapeutic agent to the suspect tissue mass; delivering a condensable vapor comprising water to the suspect tissue mass to activate the heat activated therapeutic agent; and delivering energy to heat the suspect tissue mass to destroy the suspect tissue mass from the inside out.


In embodiments, the heat activated therapeutic agent can be delivered systemically and only activated in the suspect tissue mass where the vapor is delivered.


In embodiments, the heat activated therapeutic agent is delivered via a bronchoscopic aerosol.


The agents delivered in the method may vary widely. Examples of heat activated therapeutic agents include, without limitation, a chemotherapy drug, immunotherapy agent, or a checkpoint inhibitor.


Additionally, it is to be understood that the order of the modalities may vary. In embodiments, the vapor ablation may be performed prior to the second modality or vice versa.


The invention has been discussed in terms of certain embodiments. One of skill in the art, however, will recognize that various modifications may be made without departing from the scope of the invention. For example, numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. Moreover, while certain features may be shown or discussed in relation to a particular embodiment, such individual features may be used on the various other embodiments of the invention.

Claims
  • 1. A method of treating a lung nodule in a lung, the lung nodule comprising a periphery and an interior, the method comprising: assessing the periphery of the lung nodule for symmetry, and distributing heat across the periphery of the lung nodule based on assessing the periphery of the lung nodule for symmetry, wherein the step of distributing heat is performed by advancing a catheter along an airway in the lung to a location proximal to a lung region surrounding the lung nodule and delivering a condensable vapor from the catheter into the lung region surrounding the lung nodule such that the lung nodule is engulfed or encapsulated by the condensable vapor; andassessing the interior of the lung nodule for increased tissue density for whether to apply a second ablation modality; anddirectly applying heat from a point source to the interior of the lung nodule based on the density of the interior of the lung nodule; and wherein the steps of distributing heat and directly applying heat are performed in a first treatment procedure.
  • 2. The method of claim 1 wherein the step of directly applying heat to the interior of the lung nodule comprises advancing an electrosurgical instrument into direct contact with the lung nodule, and activating the instrument.
  • 3. The method of claim 2 wherein the electrosurgical instrument is an RF energy catheter.
  • 4. The method of claim 1, further comprising delivering a therapeutic agent to the lung nodule.
  • 5. The method of claim 4 wherein the therapeutic agent is selected from the group consisting of an immunotherapy agent, sclerosing agent, and chemotherapy drug.
  • 6. The method of claim 4 wherein the therapeutic agent is an antibiotic or antiseptic agent.
  • 7. The method of claim 4 further comprising implanting microspheres in the vicinity of the lung nodule, and wherein the microspheres comprise the therapeutic agent and the therapeutic agent is released to the lung nodule from the microspheres.
  • 8. The method of claim 7 further comprising detecting the microspheres under imaging.
  • 9. The method of claim 8 wherein the imaging comprises radiography or MRI.
  • 10. The method of claim 1 wherein the condensable vapor is delivered sufficient to fill the lung region, and wherein the lung region is a segment or sub-segment of a lobe of the lung.
  • 11. A method of treating a lung nodule in a lung, the lung nodule comprising a solid mass comprising an exterior and an interior, the method comprising: identifying the exterior and interior of the solid mass;assessing tissue density of the interior relative to the exterior of the solid mass for increased tissue density;heating the lung nodule by a first modality from the whole exterior of the lung nodule inwards if the exterior of the lung nodule is less dense than the interior;heating by a second modality different than the first modality the lung nodule from the interior outwards if the interior of the lung nodule is more dense than the interior;monitoring a first ablation region and a second ablation region arising from the first modality and second modality of heating, andconfirming an overlap zone between the first ablation region and second ablation region.
  • 12. The method of claim 11 wherein the heating by the first modality comprises delivering a condensable vapor to the lung nodule.
  • 13. The method of claim 12 wherein the heating by the second modality comprises applying electrosurgical energy to the lung nodule.
  • 14. The method of claim 13 wherein the first modality is performed prior to the second modality.
  • 15. The method of claim 14 wherein the second modality is bronchoscopic radio frequency ablation.
  • 16. The method of claim 11 further comprising assessing the exterior of the lung nodule for non-uniformity prior to the step of heating by the first modality and heating by the first modality based on the assessing the exterior of the lung nodule.
  • 17. The method of claim 11 wherein the second ablation region grows outward.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of provisional patent application No. 62/556,785, filed Sep. 11, 2017, entitled “BRONCHOSCOPIC MULTIMODALITY LUNG TUMOR TREATMENT”, incorporated by reference herein in its entirety.

US Referenced Citations (263)
Number Name Date Kind
408899 Small Aug 1889 A
1719750 Bridge et al. Jul 1929 A
3507283 Thomas, Jr. Apr 1970 A
3880168 Berman Apr 1975 A
4026285 Jackson May 1977 A
4713060 Riuli Dec 1987 A
4773410 Blackmer et al. Sep 1988 A
4793352 Eichenlaub Dec 1988 A
4915113 Holman Apr 1990 A
4950266 Sinofsky Aug 1990 A
5006119 Acker et al. Apr 1991 A
5011566 Hoffman Apr 1991 A
5084043 Hertzmann et al. Jan 1992 A
5112328 Taboada et al. May 1992 A
5158536 Michael et al. Oct 1992 A
5263951 Spears et al. Nov 1993 A
5331947 Shturman Jul 1994 A
5334190 Seiler Aug 1994 A
5348551 Spears et al. Sep 1994 A
5352512 Hoffman Oct 1994 A
5424620 Cheon et al. Jun 1995 A
5462521 Brucker et al. Oct 1995 A
5500012 Brucker et al. Mar 1996 A
5503638 Cooper et al. Apr 1996 A
5524620 Rosenschein Jun 1996 A
5529076 Schachar Jun 1996 A
5549628 Cooper et al. Aug 1996 A
5562608 Michael et al. Oct 1996 A
5575803 Cooper et al. Nov 1996 A
5591157 Hennings et al. Jan 1997 A
5620440 Heckele et al. Apr 1997 A
5695507 Auth et al. Dec 1997 A
5735811 Brisken Apr 1998 A
5752965 Francis et al. May 1998 A
5755753 Knowlton May 1998 A
5782914 Schankereli Jul 1998 A
5800482 Pomeranz et al. Sep 1998 A
5824703 Clark, Jr. Oct 1998 A
5827268 Laufer Oct 1998 A
5913856 Chia et al. Jun 1999 A
5957919 Laufer Sep 1999 A
5964752 Stone Oct 1999 A
5972026 Laufer et al. Oct 1999 A
5986662 Argiro et al. Nov 1999 A
5989445 Wise et al. Nov 1999 A
6032077 Pomeranz Feb 2000 A
6053909 Shadduck Apr 2000 A
6059011 Giolo May 2000 A
6083255 Laufer et al. Jul 2000 A
6099251 Lafleur Aug 2000 A
6102037 Koch Aug 2000 A
6113722 Hoffman et al. Sep 2000 A
6130671 Argiro Oct 2000 A
6131570 Schuster et al. Oct 2000 A
6139571 Fuller et al. Oct 2000 A
6156036 Sussman et al. Dec 2000 A
6162232 Shadduck Dec 2000 A
6179805 Sussman et al. Jan 2001 B1
6194066 Hoffman Feb 2001 B1
6200333 Laufer Mar 2001 B1
6210404 Shadduck Apr 2001 B1
6219059 Argiro Apr 2001 B1
6273907 Laufer Aug 2001 B1
6283988 Laufer et al. Sep 2001 B1
6299633 Laufer Oct 2001 B1
6300150 Venkatasubramanian Oct 2001 B1
6312474 Francis et al. Nov 2001 B1
6327505 Medhkour et al. Dec 2001 B1
6394949 Crowley et al. May 2002 B1
6398759 Sussman et al. Jun 2002 B1
6398775 Perkins et al. Jun 2002 B1
6409723 Edwards Jun 2002 B1
6411852 Danek et al. Jun 2002 B1
6458231 Wapner et al. Oct 2002 B1
6468313 Claeson et al. Oct 2002 B1
6488673 Laufer et al. Dec 2002 B1
6493589 Medhkour et al. Dec 2002 B1
6508816 Shadduck Jan 2003 B2
6527761 Soltesz et al. Mar 2003 B1
6575929 Sussman et al. Jun 2003 B2
6579270 Sussman et al. Jun 2003 B2
6585639 Kotmel et al. Jul 2003 B1
6588613 Pechenik et al. Jul 2003 B1
6589201 Sussman et al. Jul 2003 B1
6592594 Rimbaugh et al. Jul 2003 B2
6599311 Biggs et al. Jul 2003 B1
6610043 Ingenito Aug 2003 B1
6629951 Laufer et al. Oct 2003 B2
6652594 Francis et al. Nov 2003 B2
6653525 Ingenito et al. Nov 2003 B2
6669694 Shadduck Dec 2003 B2
6676628 Sussman et al. Jan 2004 B2
6679264 Deem et al. Jan 2004 B1
6682520 Ingenito Jan 2004 B2
6692494 Cooper et al. Feb 2004 B1
6712812 Roschak et al. Mar 2004 B2
6719738 Mehier Apr 2004 B2
6755794 Soukup Jun 2004 B2
6770070 Balbierz Aug 2004 B1
6776765 Soukup et al. Aug 2004 B2
6860847 Alferness et al. Mar 2005 B2
6885888 Rezai Apr 2005 B2
6901927 Deem et al. Jun 2005 B2
6904909 Deem et al. Jun 2005 B2
6907881 Suki et al. Jun 2005 B2
6911028 Shadduck Jun 2005 B2
6986769 Nelson et al. Jan 2006 B2
6997189 Biggs et al. Feb 2006 B2
7022088 Keast et al. Apr 2006 B2
7027869 Danek et al. Apr 2006 B2
7031504 Argiro et al. Apr 2006 B1
7083612 Littrup et al. Aug 2006 B2
7128748 Mooradian et al. Oct 2006 B2
7136064 Zuiderveld Nov 2006 B2
7144402 Kuester et al. Dec 2006 B2
7144588 Nicholas et al. Dec 2006 B2
7174644 Critelli et al. Feb 2007 B2
7175644 Cooper et al. Feb 2007 B2
7192400 Campbell et al. Mar 2007 B2
7198635 Danaek et al. Apr 2007 B2
7233820 Gilboa Jun 2007 B2
7235070 Vanney Jun 2007 B2
7335195 Mehier Feb 2008 B2
7347859 Garabedian et al. Mar 2008 B2
7412977 Fields et al. Aug 2008 B2
7422563 Roschak et al. Sep 2008 B2
7422584 Loomas et al. Sep 2008 B2
7425212 Danek et al. Sep 2008 B1
7462162 Phan et al. Dec 2008 B2
7628789 Soltesz et al. Dec 2009 B2
7708712 Phan et al. May 2010 B2
7740017 Danek et al. Jun 2010 B2
7756563 Higgins et al. Jul 2010 B2
7778704 Rezai et al. Aug 2010 B2
7815590 Cooper Oct 2010 B2
7819908 Ingenito Oct 2010 B2
7889905 Higgins et al. Feb 2011 B2
7906124 Laufer et al. Mar 2011 B2
7913698 Barry et al. Mar 2011 B2
7985187 Wibowo et al. Jul 2011 B2
7993323 Barry et al. Aug 2011 B2
8002740 Willink et al. Aug 2011 B2
8088127 Mayse et al. Jan 2012 B2
8147532 Barry et al. Apr 2012 B2
8172827 Deem et al. May 2012 B2
8187269 Shadduck et al. May 2012 B2
8251070 Danek et al. Aug 2012 B2
8292882 Danek et al. Oct 2012 B2
8322335 Barry et al. Dec 2012 B2
8409167 Roschak Apr 2013 B2
8444636 Shadduck et al. May 2013 B2
8585645 Barry et al. Nov 2013 B2
8608724 Roschak Dec 2013 B2
8628495 Horton et al. Jan 2014 B2
8709034 Keast et al. Apr 2014 B2
8734380 Barry et al. May 2014 B2
8784400 Roschak Jul 2014 B2
8858549 Shadduck et al. Oct 2014 B2
8900223 Shadduck Dec 2014 B2
9037215 Higgins et al. May 2015 B2
9050076 Barry et al. Jun 2015 B2
9133858 Macchia et al. Sep 2015 B2
9265468 Rai et al. Feb 2016 B2
9393396 Peyman Jul 2016 B2
9913969 Roschak Mar 2018 B2
10064697 Sharma et al. Sep 2018 B2
20020077516 Flanigan Jun 2002 A1
20020111386 Michael et al. Aug 2002 A1
20020112723 Schuster et al. Aug 2002 A1
20020177846 Mulier Nov 2002 A1
20030055331 Kotmel et al. Mar 2003 A1
20030099279 Venkatasubramanian et al. May 2003 A1
20030139789 Tvinnereim Jul 2003 A1
20030181922 Alferness Sep 2003 A1
20030233099 Danaek et al. Dec 2003 A1
20040031494 Danek et al. Feb 2004 A1
20040038868 Ingenito Feb 2004 A1
20040047855 Ingenito Mar 2004 A1
20040055606 Hendricksen et al. Mar 2004 A1
20040068306 Shadduck Apr 2004 A1
20040131587 Thomas et al. Jul 2004 A1
20040199226 Shadduck Oct 2004 A1
20040200484 Springmeyer Oct 2004 A1
20040244803 Tanaka Dec 2004 A1
20050016530 McCutcheon Jan 2005 A1
20050066974 Fields et al. Mar 2005 A1
20050166925 Wilson et al. Aug 2005 A1
20050171396 Pankratov et al. Aug 2005 A1
20050171582 Matlock Aug 2005 A1
20050203483 Perkins et al. Sep 2005 A1
20050215991 Altman et al. Sep 2005 A1
20050222485 Shaw et al. Oct 2005 A1
20060004400 Mcgurk et al. Jan 2006 A1
20060047291 Barry Mar 2006 A1
20060100619 Mcclurken et al. May 2006 A1
20060130830 Barry Jun 2006 A1
20060135955 Shadduck Jun 2006 A1
20060161233 Barry Jul 2006 A1
20060162731 Wondka et al. Jul 2006 A1
20060200076 Gonzalez et al. Sep 2006 A1
20060224154 Shadduck et al. Oct 2006 A1
20070032785 Diederich et al. Feb 2007 A1
20070036417 Argiro et al. Feb 2007 A1
20070068530 Pacey Mar 2007 A1
20070091087 Zuiderveld Apr 2007 A1
20070092864 Reinhardt et al. Apr 2007 A1
20070102011 Danek et al. May 2007 A1
20070106292 Kaplan et al. May 2007 A1
20070109299 Peterson May 2007 A1
20070112349 Danek et al. May 2007 A1
20070118184 Danek et al. May 2007 A1
20070137646 Weinstein et al. Jun 2007 A1
20070293853 Truckai et al. Dec 2007 A1
20080033493 Deckman et al. Feb 2008 A1
20080132826 Shadduck et al. Jun 2008 A1
20090018538 Webster et al. Jan 2009 A1
20090043301 Jarrard et al. Feb 2009 A1
20090118538 Pizzocaro et al. May 2009 A1
20090138001 Barry et al. May 2009 A1
20090149846 Hoey et al. Jun 2009 A1
20090149897 Dacey, Jr. et al. Jun 2009 A1
20090156895 Higgins et al. Jun 2009 A1
20090192508 Laufer et al. Jul 2009 A1
20090216220 Hoey et al. Aug 2009 A1
20090301483 Barry et al. Dec 2009 A1
20090306640 Glaze et al. Dec 2009 A1
20090306644 Mayse et al. Dec 2009 A1
20090312753 Shadduck Dec 2009 A1
20100094270 Sharma Apr 2010 A1
20100185087 Nields Jul 2010 A1
20100204688 Hoey Aug 2010 A1
20100256714 Springmeyer Oct 2010 A1
20100262133 Hoey et al. Oct 2010 A1
20100310146 Higgins et al. Dec 2010 A1
20110077628 Hoey et al. Mar 2011 A1
20110118725 Mayse et al. May 2011 A1
20110160648 Hoey Jun 2011 A1
20110172654 Barry et al. Jul 2011 A1
20110257644 Barry et al. Oct 2011 A1
20110270031 Frazier et al. Nov 2011 A1
20110301587 Deem et al. Dec 2011 A1
20120016363 Mayse et al. Jan 2012 A1
20120016364 Mayse et al. Jan 2012 A1
20120289776 Keast et al. Nov 2012 A1
20130006231 Sharma Jan 2013 A1
20130267939 Barry et al. Oct 2013 A1
20130324987 Leung et al. Dec 2013 A1
20140025057 Hoey et al. Jan 2014 A1
20140088669 Lanphere Mar 2014 A1
20140163664 Goldsmith Jun 2014 A1
20140275952 Monroe et al. Sep 2014 A1
20140276713 Hoey et al. Sep 2014 A1
20150094607 Barry et al. Apr 2015 A1
20150230852 Barry et al. Aug 2015 A1
20160008050 Rajagopalan Jan 2016 A1
20160180529 Rai et al. Jun 2016 A1
20160220297 Kroon et al. Aug 2016 A1
20160310200 Wang Oct 2016 A1
20170172640 Henne Jun 2017 A1
20180055495 Tehrani Mar 2018 A1
20180318002 Barry et al. Nov 2018 A1
20190069948 Herth et al. Mar 2019 A1
20190343579 Tandri et al. Nov 2019 A1
Foreign Referenced Citations (32)
Number Date Country
721086 Jun 2000 AU
1003582 Feb 2003 EP
1143864 Feb 2004 EP
1173103 Oct 2005 EP
1326549 Dec 2005 EP
1326548 Jan 2006 EP
1485033 Aug 2009 EP
0011927 Mar 2000 WO
0102042 Jan 2001 WO
02069821 Sep 2002 WO
03070302 Aug 2003 WO
03086498 Oct 2003 WO
2005025635 Mar 2005 WO
2005102175 Nov 2005 WO
2006003665 Jan 2006 WO
2006052940 May 2006 WO
2006053308 May 2006 WO
2006053309 May 2006 WO
2006080015 Aug 2006 WO
2006116198 Nov 2006 WO
2008051706 May 2008 WO
WO-2008064026 May 2008 WO
2009009236 Jan 2009 WO
2009009398 Jan 2009 WO
2009015278 Jan 2009 WO
WO-2009009398 Jan 2009 WO
2009137819 Nov 2009 WO
2010042461 Apr 2010 WO
2011056684 May 2011 WO
2011060200 May 2011 WO
2011060201 May 2011 WO
2011127216 Oct 2011 WO
Non-Patent Literature Citations (36)
Entry
Becker, et al.; Lung volumes before and after lung volume reduction surgery; Am J Respir Crit Care Med; vol. 157; pp. 1593-1599; (1998) Oct. 28, 1997.
Blacker, G. F.; Vaporization of the uterus; J. of Obstetrics and Gynaecology; vol. 33; pp. 488-511; 1902.
Carpenter III et al.; Comparison of endoscopic cryosurgery and electrocoagulation of bronchi; Trans. Amer. Acad. Opth.; vol. 84; No. 1; pp. ORL-313-ORL-323; Jan. 1977.
clinical trials.gov.; Study of the AeriSeal System for Hyperinflation Reduction in Emphysema; 4 pages; Nov. 5, 2014; retrieved from the internet (http://clinicaltrials.gov/show/NCT01449292).
Coda, et al., “Effects of pulmonary reventilation on gas exchange after cryolytic disobstruction of endobronchial tumors,” Minerva Medical, vol. 72, pp. 1627-1631, Jun. 1981 (w/ Eng. Trans.).
Cox et al., “Bronchial Thermoplasty for Asthma.” American Journal of Respiratory Critical Care Medicine 173: 965-969 (2006).
Delaunois; Anatomy and physiology of collateral respiratory pathways; Eur. Respir. J.; 2(9); pp. 893-904; Oct. 1989.
Eyal et al.; The acute effect of pulmonary burns on lung mechanics and gas exchange in the rabbit; Br. J. Anaesth.; vol. 47; pp. 546-552; (year of publication is sufficiently earlier than the effective U.S. filing date and any foreign priority date) 1975.
Ferlay et al.; GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [internet]; 16 pages; retrieved from the Internet (http://www.iarc.fr/en/media-centre/iarcnews/2010/GLOBOCAN2008.pdf); Lyon, France: International Agency for Research on Cancer; Jun. 1, 2010.
Fishman et al., A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema, N Engl J Med, vol. 348, No. 21, pp. 2059-2073, May 22, 2003.
Goldberg et al.; Radiofrequency tissue ablation in the rabbit lung: Efficacy and complications; Acad. Radiol.; vol. 2; pp. 776-784; Sep. 1995.
Henne et al.; U.S. Appl. No. 14/957,433 entitled “Vapor treatment of lung nodules and tumors,” filed Dec. 2, 2015.
Herth et al.; Efficacy predictors of lung volume reduction with zephyr valves in a european cohort; Eur. Respir. J.; 39(6); pp. 1334-1342; Jun. 2012.
Homasson, et al., “Bronchoscopic cryotherapy for airway strictures caused by tumors,” Chest, vol. 90, No. 2, pp. 159-164, Aug. 1986.
Kang, Li, “Efficient optimal net surface detection for image segmentation—from theory to practice,” M.Sc. Thesis, The University of Iowa, Dec. 2003.
Kinsella et al.; Quantitation of emphysema by computed tomography using a “densitymask” program and correlation with pulmonary function tests; Chest; 97(2); pp. 315-321; Feb. 1990.
Looga, R. U.; Mechanism of changes in the respiratory and cardiovascular reflexes from the lungs associated with intrapulmonary steam burns; Eng. Trans. from Byulleten Eksperimental noi Biologii I Meditsiny; vol. 61; No. 6; pp. 31-33; Jun. 1966.
Marasso, et al., “Cryosurgery in bronchoscopic treatment of tracheobronchial stenosis,” Chest, vol. 103, No. 2, pp. 472-474, Feb. 1993.
Marasso, et al., “Radiofrequency resection of bronchial tumours in combination with cryotherapy: evaluation of a new technique,” Thorax, vol. 53, pp. 106-109, (year of publication is sufficiently earlier than the effective U.S. filing date and any foreign priority date) 1998.
Mathur et al., Fiberoptic bronchoscopic cryotherapy in the management of tracheobronchial obstruction, Chest, vol. 110, No. 3, pp. 718-723, Sep. 1996.
Morice et al.; Endobrinchial argon plasma coagulation for treatment of hemotysis and neoplastic airway obstruction, Chest, vol. 119, No. 3, pp. 781-787, Mar. 2001.
Moritz et al.; The effects of inhaled heat on the air pasage and lungs; American Journal of Pathology; vol. XXI; pp. 311-331; (year of publication is sufficiently earlier than the effective U.S. filing date and any foreign priority date) 1944.
Moulding et al.; Preliminary studies for achieving transcervical oviduct occlusion by hot water or low-pressure steam; Advances in Planned Parenthood; vol. 12, No. 2; pp. 79-85; (year of publication is sufficiently earlier than the effective U.S. filing date and any foreign priority date) 1977.
National Lung Screening Trial Research Team; Reduced lung-cancer mortality with low-dose computed tomographic screening; N. Eng. J. Med.; 365(5); pp. 395-409; Aug. 4, 2011.
Pieter et al.; U.S. Appl. No. 15/013,748 entitled “Medical vapor generator,” filed Feb. 2, 2016.
Pracht, Adam, “VIDA takes new approach,” Iowa City Press-Citizen, Sep. 12, 2005.
Quin, Jacquelyn, “Use of neodymium yttrium aluminum garnet laser in long-term palliation of airway obstruction,” Connecticut Medicine, vol. 59, No. 7, pp. 407-412, Jul. 1995.
Sciurba et al.; A randomized study of endobronchial valves for advanced emphysema; N. Eng. J. Med.; 363(13); pp. 1233-1244; Sep. 23, 2010.
Shah et al.; Collateral ventilation and selection of techniques for bronchoscopic lung volume reduction; Thorax; 67(4); pp. 285-286; Apr. 2012.
Slebos et al.; Bronchoscopic lung volume reduction coil treatment of patients with severe heterogeneous emphysema; Chest; 142(3); pp. 574-582; Sep. 2012.
Sutedja, et al.; Bronchoscopic treatment of lung tumors; Elsevier, Lung Cancer, 11, pp. 1-17, Jul. 1994.
Tschirren et al.; Intrathoracic airway trees: segmentation and airway morphology analysis from low-dose CT scans; IEEE Trans. Med. Imaging; vol. 24, No. 12; pp. 1529-1539; Dec. 2005.
Tschirren, Juerg; Segmentation, anatomical labeling, branchpoint matching, and quantitative analysis of human airway trees in volumetric CT images; Ph.D. Thesis; The University of Iowa; Aug. 2003.
Tschirren, Juerg; Segmentation, anatomical labeling, branchpoint matching, and quantitative analysis of human airway trees in volumetric CT images; Slides from Ph.D. defense; The University of Iowa; Jul. 10, 2003.
Van De Velde; Vapo-cauterization of the uterus; Amer. J. Med. Sci.; vol. CXVIII; (year of publication is sufficiently earlier than the effective U.S. filing date and any foreign priority date) 1899.
Vorre et al.; Morphology of tracheal scar after resection with CO2-laser and high-frequency cutting loop; Acta Otolaryngol (Stockh); vol. 107; pp. 307-312; (year of publication is sufficiently earlier than the effective U.S. filing date and any foreign priority date) 1989.
Related Publications (1)
Number Date Country
20190076189 A1 Mar 2019 US
Provisional Applications (1)
Number Date Country
62556785 Sep 2017 US